We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




USP15 Promotes Brain Cancer by Activating the TGF-beta Pathway

By LabMedica International staff writers
Posted on 07 Mar 2012
The USP15 protein has been identified as a potential therapeutic target that may accelerate drug development against glioblastoma and certain other types of cancer.

Investigators at the Vall d'Hebron Institute of Oncology (Barcelona, Spain) reported in the February 19, 2012, online edition of the journal Nature Medicine that they had identified the de-ubiquitinating enzyme ubiquitin-specific peptidase 15 (USP15) as a key component of the TGF-beta signaling pathway, and that USP15 promoted tumor progression by activating the TGF-beta pathway.

The TGF-beta pathway controls proliferation, cellular differentiation, and other functions in most cells. More...
It plays a role in immunity, cancer, heart disease, and diabetes. TGF-beta acts as an antiproliferative factor in normal epithelial cells and at early stages of cancer development. In normal cells, TGF-beta, acting through its signaling pathway, stops the cell cycle at the G1 stage to stop proliferation, induce differentiation, or promote apoptosis. When a cell is transformed into a cancer cell, parts of the TGF-beta signaling pathway are mutated, and TGF-beta no longer controls the cell. These cancer cells and surrounding stromal cells (fibroblasts) begin to proliferate. Both types of cell increase their production of TGF-beta. This TGF-beta acts on the surrounding stromal cells, immune cells, endothelial, and smooth muscle cells. It causes immunosuppression and angiogenesis, which makes the cancer more invasive. TGF-beta also converts effector T-cells, which normally attack cancer with an inflammatory reaction, into regulatory (suppressor) T-cells, which turn off the inflammatory reaction.

USP15 was also found to stabilize type I TGF-beta receptor (TbetaR-I), leading to an enhanced TGF-beta signal. High expression of USP15 correlated with high TGF-beta activity, and the USP15 gene was found to be amplified in glioblastoma, breast, and ovarian cancer. USP15 amplification conferred poor prognosis in individuals with glioblastoma.

The important role of USP15 was confirmed by the finding that downregulation or inhibition of USP15 in a patient-derived mouse model of glioblastoma decreased TGF-beta activity. Moreover, depletion of USP15 decreased the oncogenic capacity of patient-derived glioma-initiating cells due to the repression of TGF-beta signaling.

Senior author Dr. Joan Seoane, director of translational research at the Vall d'Hebron Institute of Oncology, said, “When we inhibited USP15 in a real model of human glioblastoma, TGF-beta activity decreased and the tumor did not develop. USP15 regulates tumor progression and is critical in cancer.”

Related Links:
Vall d'Hebron Institute of Oncology



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.